A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Syndax Pharmaceuticals, Inc. SNDX
Promising (early) broader-coverage candidate · Syndax Pharmaceuticals, Inc.
On FrontierLab's discovery record since 2026-07-08 (6 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-18), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 222.3% |
|---|---|
| Gross margin | 97.5% |
| Gross profits / assets | 0.35 |
| Rule of 40 | 145.2 |
| Net margin | -77.1% |
| Cash runway (months) | 29.8 |
| PEG | — |
| Price / sales | 6.9 |
Quality checklist
- ✓ Revenue growth — 222.3% (pass ≥ 20%)
- ✓ Capital efficiency
- ✓ Gross margin — 97.5% (pass ≥ 60%)
- ~ Gross-margin trend — 0.3 (pass ≥ 2)
- ✓ Share dilution — 3.1%
Fundamentals — snapshot as of 2026-08-18
| Stage | Early |
|---|---|
| Share issuance (YoY) | 3.1% · modest issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-2.52 |
| Burn multiple | 0.9 |
| Gross-margin trend (pts) | 0.3 |
| Cash / assets | 0.78 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-04 |
Momentum context — a snapshot from 2026-08-18, not current
| Price at surface | $19.76 (as of 2026-08-18) |
|---|---|
| 52-week range | $12.99 – $25.59 |
| % off 52-wk high | -22.8% |
| RSI (14) | 45 |
| Relative volume | 0.8× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-18 (end-of-day). How grades are computed →